why choose us

First received: January 13, 2023

Clinical Trial: Janus Kinase Inhibition in Sarcoidosis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Sarcoidosis

Study Type: INTERVENTIONAL


Official Title: JAK1 Inhibition in Sarcoidosis: an Opportunity for Pathogenesis Directed Therapy

Brief Summary: The purpose of this study is to investigate the role of the oral JAK1 inhibitor, abrocitinib 200 mg once daily, for the treatment of patients with moderate to severe cutaneous sarcoidosis.

Read more